- Home
- MNY vs XLO Comparison
MNY vs XLO Comparison
Compare MNY & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNY | XLO |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | Singapore | United States |
| Employees | 240 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 49.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNY | XLO |
|---|---|---|
| Price | $0.94 | $9.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 65.3K | 38.0K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.58 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.78 | $0.46 |
| 52 Week High | $2.40 | $9.89 |
Technical Indicators
Market Signals| Indicator | MNY | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 50.83 |
| Support Level | $0.78 | $7.47 |
| Resistance Level | $1.03 | $8.97 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 64.00 | 29.10 |
Price Performance
Historical ComparisonAbout MNY MoneyHero Limited
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.